Sutro inks $390M roy­al­ty fi­nanc­ing deal with Black­stone; Clin­i­cal hold on Phar­varis' HAE drug lift­ed

Sutro Bio­phar­ma is land­ing a $140 mil­lion up­front in ex­change for hand­ing off its roy­al­ty in po­ten­tial fu­ture sales of Vax­cyte’s can­di­dates.

The deal, an­nounced Mon­day, is with Black­stone — which al­lows up to an­oth­er $250 mil­lion in fu­ture mile­stone pay­ments for Sutro’s 4% roy­al­ty on Vax­cyte’s prod­ucts. Sutro says the trans­ac­tion gives it non-di­lu­tive growth cap­i­tal, al­low­ing it to con­tin­ue ad­vanc­ing its pipeline and de­vel­op­ing cell-free pro­tein syn­the­sis tech­nol­o­gy fur­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER